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Abstract
Pharmacology, in its broadest interpretation, is defined as the study of the interaction between
physiological entities and drugs. In modern neuropsychopharmacology, this interaction is viewed
as the drug itself on one side and signal transducer (receptor), the signal transduction cascade
(effector proteins, second messengers), the cellular response (transcriptional regulation, activity
modulation), the organ response (brain circuitry modulation), and, finally, the whole organism
response (behavior) on the other. In other words, pharmacology has structured itself around the
idea that the exogenous molecule (the drug) encodes a “signal” leading to everything on the other
side including, in extreme renditions, a physiological response. The inference is that engaging a
particular signal transduction pathway in a defined cell type leads inexorably to a prototypic
physiological response. Thus, for instance, serotonergic activation of 5-HT2A receptors in rat
aortic smooth muscle cells leads to an increase in intracellular Ca++ (via IP3 release) and smooth
muscle contraction (Roth et al., 1986). Here, we suggest that the invention of synthetic ligand –
GPCR pairs (aka DREADDs, RASSLS, ‘pharmacogenetics’) permits the study of pharmacology
using a shifted equation: more of the signal transduction elements moved to the left and,
subsequently, under experimental control. For the purposes of disambiguation and to clarify this
new interpretation as a creation of pharmacological manipulation, we present the term
pharmacosynthetics to describe what has heretofore been called pharmacogenetics or
chemicogenetics. This review discusses this new interpretation and reviews recent applications of
the technology and considerations of the approach.
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1. INTRODUCTION
The gap between receptor mediated signaling and the ultimate functional output of the brain
is shrinking. The past decade has witnessed the advent of multiple technologies that allow
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exquisite manipulation of neurons in an intact animal, providing the opportunity to
definitively determine the neuronal correlates of complex brain function. The primary
technologies are optogenetic – the modulation of transgenic receptors and channels via
photons-- and pharmacogenetic – the modulation of transgenic receptors via pharmacologic
agents. This review will focus on pharmacogenetics.
First and foremost, the authors present an alternative name for this technology to
disambiguate the topic from other uses of the word pharmacogenetic. The term
“pharmacogenetic” is already an established MeSH (Medical Subject Headings) term,
defined as “a branch of genetics which deals with the genetic variability in individual
responses to drugs and drug metabolism.” This word has been well adopted, retrieving 3318
results from PubMed as of publishing date, has been in use for an extended period of time
(Gonzalez-Vacarezza et al., 2012; La Du, 1972; Weinshilboum et al., 1999) and is the
foundation of personalized medicine (Cohen, 1997; Kohane, 2012). For similar reasons, the
term “chemical genetics” (or its portmanteau chemicogenetic), while not being assigned its
own MeSH term, has been defined as “the study of gene-product function in a cellular or
organismal context using exogenous ligands” (Stockwell, 2000). Here we present alternative
terminology and reimagination of pharmacogenetics (the modulation of transgenic receptors
via pharmacologic agents) as pharmacosynthetics. This term integrates the true meaning and
functional mechanisms of the technology: pharmaco- meaning drug and -synthetic meaning
the combination of two or more parts in an artificial manner. Pharmacosynthetics provides a
clear distinction from both pharmacogenetics and chemicogenetics, and as of publishing
date, retrieves no results in PubMed or Wikipedia.
We present the formal definition of pharmacosynthetics as “a branch of biology which deals
with the creation of pharmacological modulation using artificial components”. While it is
possible to equate conventional drugs with pharmacosynthetics (or having been developed
through pharmacosynthesis), there are distinctions within the semantics that should be
explored to provide clarification. A chemical is synthesized to have a particular
pharmacology, and this pharmacology is based on the system that the chemical interacts
with. On the other hand, a pharmacosynthetic approach creates a pharmacological response
within a system using artificial components. While a pharmacological agent may be
synthesized, at no point in this effort is the pharmacology of the agent created – instead, it is
measured. In one way of thinking about it, a pharmacology (as defined as the study of drug
action) is synthesized for an otherwise inert chemical by engineering a receptor and inserting
the receptor into a living system. On the other hand, when a novel chemical is synthesized,
its pharmacology in a living system is studied to determine whether or not it is a drug.
The pharmacosynthetic tools currently utilized include the Designer Receptors Exclusively
Activated by Designer Drug (DREADDs), the latest iteration of a long-standing concept of
creating orthologous ligand-receptor pairs to remotely control cellular GPCR signaling
(Conklin et al., 2008). The original DREADDs were human muscarinic acetylcholine
receptors engineered to be activated by clozapine N-oxide (CNO), an otherwise inert
pharmacological agent. Additionally, DREADDs are insensitive to the endogenous ligand,
acetylcholine. There are currently three DREADDs in common use – the hM3Dq that
activates Gαq signaling, the hM4Di that activates Gαi signaling, and the rM3Ds that
activates Gαs signaling. These three DREADDs share the same point mutations (Figure 1)
that simultaneously engender CNO efficacy and acetylcholine inefficacy (Armbruster et al.,
2007). The rM3Ds was engineered to couple Gαs by replacing intracellular loops 2 and 3 of
the hM3Dq with those from the turkey β1-adrenergic receptor (Guettier et al., 2009). With
these three DREADDs, it is possible to control the most common types of G-protein
signaling found in the mammalian brain.
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Connecting receptor mediated signaling to overt brain function is the defining challenge of
neuropsychopharmacology research. The hypothesis that aberrant neuronal activity underlies
neuropsychiatric disease and the knowledge that drugs modulate neuronal activity via
receptors has fueled the persistence of this challenge. To date, small molecule therapeutics
are the first line treatments for debilitating mental illness including schizophrenia,
Parkinson's disease, and depression, to name a few. DREADDs offer a unique opportunity to
study the neurophysiological correlates of therapeutic efficacy due to the nature of the
DREADD technology and therapeutic mechanisms of efficacy. First and foremost,
DREADDs are G-protein coupled receptors – a drug target class of which 36% of all
currently approved drugs either directly or indirectly modulate (Klabunde and Hessler,
2002). Furthermore, DREADDs are modulated in a drug-like fashion since the small-
molecule ligand exhibits drug-like pharmacokinetics. Finally, it has been observed that
therapeutic efficacy is most often obtained through modulation of diffusely expressed albeit
specific drug targets (Roth et al., 2004). These three characteristics can only be mimicked
via systemic injection of drug and genomic transgene-driven dispersed expression of the
DREADD. This similarity to conventional therapeutics will allow an immediate crossover of
insights gleaned from research utilizing DREADDs to the physiological phenomena
responsible and necessary for therapeutic efficacy.
DREADDs are capable of providing non-invasive temporal control of neuronal signaling for
three important reasons that clearly distinguish DREADDs from previous
pharmacosynthetic technology. The first is the two-way selectivity of the receptor-ligand
pair, in that CNO does not modulate other known effectors in a biological system and that
the engineered receptor is not activated by effectors present in the biological system.
Secondly, DREADDs do not exhibit constitutive activity – i.e., in the absence of CNO, the
DREADDs do not modulate neuronal signaling. The variant rM3Ds has been shown to
exhibit constitutive activity in pancreatic beta cells (Guettier et al., 2009), though
constitutive activity was not observed in striatal neurons (Farrell, In revision). Finally, the
drug used to activate the DREADD is bio-available and drug-like, meaning that a simple
administration method (injection, drinking water, food, etc.) can be used to modulate
DREADD activity. These advancements are perhaps the most important in terms of the
ultimate goal of neuropsychopharmacology, as it permits the investigation of specific
signaling states on changes in overt animal behavior with minimal invasiveness.
For a review of the primary research and development of pharmacosynthetics, the reader is
directed to Rogan & Roth (2011) in which the hM3Dq and hM4Di neuronal validation is
reviewed in addition to the original technology development. The reader is also directed to
other published reviews on DREADDs and RASSLs (Conklin et al., 2008; Dong et al.,
2010; Pei et al., 2008). This review will focus on the uses of DREADDs in the intervening
years and will also provide a novel perspective on this technology.
2. Gs-DREADD (rM3Ds) neuronal validation
The most recent of the DREADDs to be validated is the Gs-DREADD (rM3Ds). The rM3Ds
was originally validated in pancreatic beta islet cells by Guettier et al., 2009. To determine
whether the rM3Ds could modulate neuronal Gs-type signaling, Farrell et al, (In revision)
created a transgenic mouse expressing the rM3Ds in the striatum. The striatum is a nucleus
of the basal ganglia, an area of the brain responsible for volitional movements and reward
processes (DeLong and Wichmann, 2009). The nucleus is comprised of two distinct
populations of medium spiny neurons (MSNs) that project to unique downstream basal
ganglia nuclei. Additionally, these two populations have unique cellular expression profiles.
The striatonigral MSNs project to the internal globus pallidus and substantia nigra pars
reticulata and express dopamine D1 receptors, substance P and dynorphin peptides, whereas
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the striatopallidal MSNs project to the external globus pallidus and express dopamine D2
receptors and enkephalin peptides (Gerfen et al., 1990; Svenningsson et al., 1998). Activity
of the striatopallidal MSNs inhibits behavior (DeLong, 1990; Kravitz et al., 2010) and Gs-
type signaling in MSNs is thought to promote neuronal excitability (Centonze et al., 2001;
Surmeier et al., 2007). The rM3Ds was expressed in the striatopallidal MSNs using the
adenosine A2A bacterial artificial chromosome to create the adora2A-rM3Ds mice. The
transgene contains a mCherry fluorescent reporter downstream of an internal ribosomal
entry site (IRES), and expression targeting of the transgene was confirmed by crossing the
adora2A-rM3Ds mice with the GENSAT Drd2-GFP and Drd1a-GFP reporter mice.
Biochemical studies confirmed that the rM3Ds signals through canonical Gs-signaling
cascades in these mice by quantifying the phosphorylation of DARPP-32 at Thr34, a well-
studied downstream target of the Gs / cAMP / PKA signaling cascade in MSNs (Ouimet et
al., 1984; Svenningsson et al., 2004). Administration of CNO caused a significant inhibition
of novelty-induced locomotor activity and a dose-dependent decrease in spontaneous
locomotor activity during the dark phase. These studies confirm that the rM3Ds signals via
canonical Gs-type cascades in a neuronal environment.
The validation study was extended by testing the effects of rM3Ds activation in an animal
model of addiction. Drugs of abuse modulate the biochemical processes of the basal ganglia,
with dopaminergic signaling being of unique significance for psychostimulants. This class
of drugs, which include the drugs methamphetamine, cocaine, and recently popular
mephedrone, directly increase the amount of dopamine present in the basal ganglia
(McKenzie and Szerb, 1968; Sulzer, 2011). Psychostimulants cause a hyperlocomotor
response in rodents, and repeated administration of a constant dose causes an enhanced
locomotor response. This increased locomotor activity in response to a constant dose of
psychostimulant is a manifestation of behavioral sensitization, which has become a well-
studied animal model of addiction (Steketee and Kalivas, 2011). While the exact neuronal
correlates of sensitization are unknown, the role of dopaminergic signaling in the MSNs has
been heavily implicated (Narendran and Martinez, 2008) . Overactivity of the D2 receptor in
the striatopallidal MSNs could, for example, induce neuronal modifications that cause these
neurons to become less sensitive to neuronal input, thus causing an increased behavioral
response to the same dose of drug. The dopamine D2 receptor inhibits cAMP production via
Gi modulation, so it was hypothesized that increasing cAMP signaling via rM3Ds-Gs
activity would counteract the effects of repeated amphetamine treatment. When CNO was
co-administered with amphetamine for 5 consecutive days, the adora2A-rM3Ds mice did not
develop locomotor sensitization. After 10 days of no drug treatment, mice were injected on
day 15 with amphetamine alone and their locomotor activity recorded. The adora2A-rM3Ds
mice that had been treated with amphetamine and CNO did not show sensitization
expression. Furthermore, measurements of striatopallidal MSN excitability confirmed that
CNO co-administration reversed changes in membrane conductance caused by amphetamine
treatment. The behavioral data recapitulate endogenous Gs signaling phenomena, as it has
previously been shown that pharmacological modulation of Gs signaling in these neurons
via the adenosine A2A receptor can inhibit amphetamine sensitization (Shimazoe et al.,
2000). Thus, these data provide further validation that the rM3Ds signals through canonical
Gs-signaling pathways in a neuronal context and demonstrate the utility of the DREADD
technology in the study of disease etiology.
3. Application of pharmacosynthetics
3.1. Selective mimicry of endogenous receptors
One application of pharmacosynthetics is to use them as very selective pharmacological
agents. In this manner, DREADDs can be expressed in a neuronal population that matches a
pharmacologically intractable endogenous receptor. The Gs-DREADD validation study
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described above can be viewed as an example of this type of application, in which the
DREADD enabled selective modulation of a distinct population of neurons residing in a
nucleus of heterogenous neuronal composition. In this study, the Gs-DREADD was driven
by the adora2A gene in a bacterial artificial chromosome. In the mouse genome, the native
adora2A gene drives the expression of the adenosine A2A receptor, which itself is a Gs-
coupled receptor. To date, the availability of selective adenosine A2A agonists is limited,
and CGS 21680 is the most commonly used. Thus, by mimicking the expression of the
adenosine A2A receptor with the Gs-DREADD, we essentially created a highly selective
adenosine A2A receptor ligand-pair. Utilizing the DREADD as a selective mimicry is
limited, though, in that the DREADD must be of the same coupling-type as the endogenous
receptor for which it is mimicking. In the instance above, the Gs-DREADD and the
adenosine A2A receptor both couple to Gs signaling pathways. Indeed, the advent of
functional selectivity (a.k.a agonist-directed trafficking, biased agonism) introduces
complications (or potential benefits) that will be discussed in section 5.1. One can imagine
applying pharmacosynthetics in this manner to study the effects of orphan receptor
modulation, receptors with unique neuronal expression patterns with no known modulators.
3.2. Creating drug-like modulation where none exists
Additionally, the DREADD system can be conceptualized of as a way to pharmacologically
modulate spatially defined neuronal populations for which no pharmacological modulatory
agents exist. Krashes et al. (2011) used DREADDs in this fashion to study the arcuate
nucleus (ARC) of the hypothalamus. This nucleus has been implicated in regulating energy
homeostasis and has therefore been a focus of study for the understanding and treatment of
obesity, with particular focus on agouti-related protein (AgRP) neurons expressed in this
nucleus. To date, investigative efforts into the function of these neurons have been limited to
conventional genetic, invasive, and ablative approaches: overexpression of AgRP in
transgenic mice, central administration of peptides, and ablation of AgRP neurons. The first
approach removes the temporal specificity required for definitive experimentation, whereas
the latter approaches introduce confounds associated with non-reversible and invasive
administration techniques. Krashes et al. (2011) utilized DREADD technology to study the
acute effects of AgRP neuronal activity. The hM3Dq DREADD was targeted to AgRP
neurons using a Cre-recombinase dependent adeno-associated virus (AAV) injected into
AgRP-Ires-cre mice. Following i.p. administration of CNO (0.3 mg/kg), hM3Dq-expressing
mice began feeding and ate almost four times as much food than control mice in the first
half hour. Additionally, this group infected the same neurons with the hM4Di to induce
neuronal silencing and observed a decrease in food intake. This study demonstrates that
DREADDs can be used to introduce pharmacological modulation to nuclei for which drug-
like compounds do not exist.
A similar approach was used to modulate orexin neurons in the lateral hypothalamic area.
These neurons have been implicated in sleep and wakefulness and produce neuropeptides
orexin A and orexin B. As mentioned above, the pharmacological modulation of
neuropeptide systems is historically difficult due to issues of invasiveness (local
microinjection of purified peptide), lack of temporal control (genetic modulation) or off-
target effects (physical ablation). Using virally mediated gene transfer, Sasaki et al. (2011)
was able to express the hM3Dq and hM4Di in the orexin neurons of the lateral hypothalamic
area. Following intraperitoneal administration of CNO (5.0 mg/kg) during the light phase
(when mice typically sleep), the percent of wakefulness during the following hour was
significantly greater and the NREM time was significantly shorter. Similarly, administration
of CNO during the dark phase (when mice are typically awake), caused significant increase
in wakefulness. Conversely, administration of CNO to mice expressing the hM4Di (the
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inhibitory DREADD) in the orexin neurons decreased wakefulness during the dark phase
and the light phase.
Introducing pharmacological modulation to non-druggable neuronal populations was also
demonstrated by Ray et al. (2011). Here, the hM4Di (referred to as Di in the report) was
expressed in serotonergic neurons of the brainstem using conditional intersectional genetics.
In normal mice, an increase in the amount of carbon dioxide inhaled causes an increase in
breathing. Upon administration of CNO (10 mg/kg), the hM4Di transgenic mice had a
blunted response to increased CO2 concentrations. These data indicate that the serotonergic
neurons of the brainstem are involved in the modulation of respiratory activity. Additionally,
they found that CNO injection decreased oxygen consumption in room air independent of
ventilation modulation, indicating that these neurons can modulate metabolic rate
independent of respiration. Furthermore, this group found that modulation of these neurons
caused long-term changes in body temperature (up to 10 hours in duration), and that this
effect became desensitized following repeated CNO treatment.
3.3. Encoding and modulating diffuse neuronal ensembles
A very elaborate application of pharmacosynthetics was performed by Garner et al. (2012)
in which the neuronal ensemble encoding a memory trace was captured and recreated by
DREADDs. To achieve this engram capturing ability, a transgenic mouse was designed to
express the hM3Dq in active neurons during a conditioning task. This was achieved using a
c-fos promoter-driven tTa transgenic mouse crossed with the TRE-hM3Dq mouse. The
protein c-fos is a transcription factor that is upregulated in response to increases in neuronal
activity. Thus, by using the c-fos promoter sequence, the active neurons of transgenic mice
are labeled with hM3Dq receptor. These labeled neurons can then be activated via CNO
administration to re-create the neuronal activity pattern responsible for the initial neuronal
labeling. Garner et al. used these mice to determine whether a synthetic memory trace could
be formed and re-created using pharmacosynthetics. To do this, they used a fear
conditioning protocol in which a mouse is electrically shocked in a novel environment. In
this paradigm, a mouse learns very quickly that particular environments are associated with
an electric shock, and when later placed in the shock-paired environment will “freeze” – a
well characterized behavior associated with learned fear. During these sessions, the neurons
involved in the formation of these memories will become more active and thus express the
hM3Dq. Interestingly, they found that the synthetic memory trace encoded by the
DREADD-tagging could not produce a fear response on its own. The DREADD-encoded
memory trace, however, was powerful enough to interfere with a naturally encoded memory
trace. This study exemplifies the ability of pharmacosynthetics to modulate a diffuse but
specific population of neurons.
3.4. Long-lasting specific neuronal modulation
A useful aspect of pharmacological modulation is the duration of activity inherent in the
pharmacological approach. In addition to the pharmacokinetics of CNO activation, the
hM3Dq, hM4Di, and rM3Ds have been shown to produce long-lasting neuronal modulation
exceeding what can be explained by pharmacokinetics alone (see table 1 for summary). This
longevity of action can be utilized in studies requiring chronic modulation of neuronal
activity. For example, to determine the influence of neuronal circuit activity on excitatory
synaptogenesis in medium spiny neurons, Kozorovitskiy et. al (2012) administered a chronic
regimen of CNO (1.0 mg/kg, twice-daily, from post-natal day 8-15) to mice pups that had
been infected at post-natal day 0-1 with an AAV carrying a cre-dependent hM4D. In this
study, D1 and D2-Cre mice were used to target expression of the hM4Di in the two primary
neuron populations of the striatum. The chronic regimen of CNO administration, theorized
to produce long-lasting neuronal activity modulation, dampened synaptogenesis of direct or
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indirect pathway MSNs as measured by mEPSC frequency and spine density on day 15 in
mice expressing hM4Di throughout the striatum. In mice expressing the hM4Di unilaterally
in a more dispersed manner (theorized to not effect circuitry activity), there was no effect of
CNO on synaptogenesis. To determine whether the corticostriatal neurons (those that project
to the striatum from the cortex) could influence synaptogenesis, the hM4D AAV was
injected to the Rbp4-cre mouse, a mouse expressing Cre in corticostriatal neurons. These
mice were treated with the same chronic regimen of CNO. On day 15, decreased mEPSC
frequency and spine density was observed, indicating a decrease in synaptogenesis. Similar
results were also observed when measured at postnatal day 25-28, indicating these changes
persist into adulthood. This study demonstrates the ability of the pharmacosynthetic
approach to provide chronic neuronal modulation.
4. Considerations and Implications of the above studies
Pharmacosynthesis requires consideration of multiple factors to be utilized effectively. The
key elements to be considered are the expression of DREADD and the dose of CNO
required for experimental manipulation. Here we provide a primer on the consideration of
these elements.
4.1. Expression systems
The primary challenge in pharmacosynthetics is inserting the DREADD receptor into the
desired tissue of the model organism. To date, this has been achieved using virally mediated
gene transfer and genomic insertion of a transgene. Although a full review of each approach
is beyond the scope of this manuscript, the benefits and complications of each approach will
be briefly discussed.
4.1.1. Virally Mediated Gene Transfer—Virally mediated gene transfer utilizes viral
mechanisms to insert the DREADD DNA into a neuronal population. There are many
different types of viruses available, each having their own benefits and drawbacks. The
reader is directed to reviews and applications of viral vectors and their utility (de Silva and
Bowers, 2011; Foust et al., 2009; Teschemacher et al., 2005; Weinberg et al., 2012; Wu et
al., 2006). The primary benefit of the viral approach is the relative turnaround between
project conception and functional animal model expressing the DREADD. In addition to the
expediency provided by this approach, the local microinjection of viral particles enhances
the spatial specificity of DREADD expression. Finally, the viral approach permits utilization
of the DREADD in model organisms for which transgenic approaches are not available or
widespread (e.g., rats, monkeys). The drawbacks of the viral approach arise from the nature
of local microinjections and the size limitations of viral packaging. This vector delivery
method is invasive, potentially inducing an immune response and causing damage to tissue,
including cell populations either directly or indirectly involved in the scrutinized output.
Additionally, the spatial resolution provided can also be a limitation, in that DREADD
expression is limited to the number of microinjection sites and the spread of viral particles.
This latter point, however, can be a benefit depending on the goals of the study.
Furthermore, the expression pattern of DREADDs between animal subjects will not be
precisely identical due to differential stereotactic coordinate alignment, inconsistent viral
diffusion, and experimental variation. Finally, viruses are only capable of carrying a certain
quantity of DNA, potentially limiting the addition of desirable vector traits including
targeting information (promoter sequences) and cell-type markers (fluorescent proteins).
4.1.2. Genomic Insertion of Transgene—Genomic insertion of a DREADD-encoding
transgene involves the creation of a new line of genetically modified mice or the selective
breeding of extant transgenic lines. The benefits of the transgenic approach are inherent to
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genome-level insertion of a transgene. First and foremost, the transgenic line of mice carries
the transgene and expresses the DREADD in accordance to the genetic information in the
transgene. Thus, no invasive interventions are necessary to obtain DREADD expression,
providing a truly non-invasive means of cell-type specific signaling. Secondly, DREADDs
can be expressed in a more dispersed manner using a transgenic approach. Whereas virally
mediated gene transfer can only provide expression of the DREADD in the range of viral
diffusion, the transgene inserted into the genome is present in all cells. Expression of the
DREADD is dependent upon the information contained in the transgene, and while the
genetic sequences that confer cell-type specificity of expression are still a matter of research,
certain promoter sequences have been determined. Thus, while the noninvasive component
is definitively beneficial, the utility of dispersed expression patterns is dependent upon the
research goals.
One type of transgenic approach is to create a new transgenic line to suit the needs of the
intended research. When creating a new line of DREADD transgenic mice, the DREADD-
encoding construct is inserted downstream of a promoter that is useful for the research goal.
For instance, the Gs-DREADD mice described above utilized the adenosine A2A receptor
BAC to drive DREADD expression in striatopallidal medium spiny neurons, an area where
the adenosine A2A receptor is naturally enriched. This permitted for the selective activation
of Gs signaling in those neurons in mice carrying a single transgene. One benefit of the
single transgene approach is breeding efficiency: hemizygous breeding strategies can
produce 50% transmission with the end result being 50% of the litter can be used for study.
Additionally, because the cell-type specificity is transmitted in one transgene, these mice
can be easily crossbred with other types of engineered mice. The downside of this approach
is that these single-transgene mice can only be used to study the cell population originally
intended. An additional downside is that efforts to identify the genetic information
responsible for tissue targeting have been, for the most part, unsuccessful, though a select
few promoters have been commonly used in neuroscience research. One way to overcome
this lack of knowledge is to knock-in the transgene, such that the endogenous promoter for a
given neuronal subtype carries the DREADD sequence in addition to the endogenous gene
product. To avoid interfering with a particular genomic locus, an alternative transgenic
strategy is to create a transgene containing the entirety of the genetic information associated
with a particular cell-type specific protein. This approach can be achieved by using bacterial
artificial chromosomes (BACs), which are capable of carrying 200-300 kb of genetic
information, a drastically larger amount than other transgenic approaches utilize (Heintz,
2001). For instance, the camKII-alpha promoter sequence is 8.5 kb (Tsien et al., 1996),
whereas the adora2A BAC is 175 kb. Finally, creating a transgenic mouse is both resource
intensive and the effort has no guaranteed yield, depending on the strategy.
Alternatively, targeting DREADD expression to a cell type of interest can be achieved using
conditional intersectional genetics. This approach involves the selective breeding of extant
transgenic lines to produce mice carrying multiple transgenes; i.e., polytransgenic mice. In
these mice, the expression specificity of the DREADD depends on the design of the
transgenes, an approach called “intersectional genetics”. A handful of technologies are
available for this approach and the number of transgenic mice carrying these technologies is
ever expanding. Prominently in use are the Cre, Flp, and Tet technologies, all of which are
based on proteins and DNA sequences exogenous to the targeted model organism (in this
case, the mouse) (Mallo, 2006). The Cre and Flp systems are based on the recombinases and
their associated DNA targeting sequences. In these systems, one mouse carries a transgene
for the Cre or FLP protein in which the protein sequence is downstream of a promoter that
drives expression in a particular cell population (cell population A). A second mouse has a
separate transgene, in which the DREADD sequence is inserted downstream of a ubiquitous
promoter followed by a stop cassette that is flanked by either the Cre excision sites (LoxP)
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or the Flp excision site (Flpe). Thus, in the cell population that expresses Cre or Flp, the stop
cassette is removed from the genetic sequence. The nuclear expression machinery can then
translate the DREADD sequence into protein in that cell population. In the cells that do not
express Cre or Flp, the DREADD transgene remains silent due to the presence of the stop
cassette. The Cre / Flp systems can also take advantage of a second phenomenon of the
recombinatorial proteins in that they can reverse the direction of the sequence between the
excision sequences. Dependent upon the orientation of the excision sequences, the Cre and
Flp can either excise the bookended DNA or flip the direction. The “reversal” approach is
less leaky than the excision method; i.e., the intended specificity of expression is more likely
to occur.
In the Tet system, one mouse is designed with a transgene containing the tet trans-activator
(Tta) sequence downstream of a cell-type specific promoter. A second mouse is designed
with a transgene containing the DREADD sequence downstream of the tet-response element
(TRE) sequence. When the two mice are interbred to create double-transgenic offspring, the
tet trans activator binds to the tet response element and permits DREADD expression. This
system also permits for temporal control by the administration of doxycycline to the
organism. Doxycycline binds to the trans activator and blocks its interaction with the tet
response element, ultimately inhibiting expression of the DREADD. Alternatively, the
reverse trans activator (rTta) can be used, in which doxycycline administration is necessary
for the interaction of the trans activator and the response element. In this version of the
system, doxycycline can be administered to induce the expression of the DREADD. The tet
system has been enhanced recently with the tet-on 3G system (Clontech), but the underlying
principles remain.
4.1.3. Combinatorial approaches—Already the world of neuroscience research is
seeing the full implementation of these technologies and the benefits of combining them.
For example, the Krashes et al. (2011) and Sasaki et al. (2011) studies combined the
specificity of expression provided by the genomic transgene approach with the spatial
resolution and quick turnaround of the viral approach to achieve cell-type specific neuronal
modulation. The Ray et al. (2011) study used intersectional genetics to increase the
specificity of DREADD expression with minimal invasiveness. At this point, the ability to
target DREADD expression to specific tissue populations depends on the transgenic state of
the art.
4.2. CNO Doses and Routes of Administration
In the articles mentioned above, a range of CNO doses is used to obtain effects at the whole-
organism level, and these doses are summarized in Table 1. The dose of CNO required
varies depending on the expression system, localization of expression and type of
DREADD. For example, the hM3Dq DREADD is very effective at depolarizing neurons,
and thus, relatively low doses can be used to elicit an effective neuronal response
(Alexander et al., 2009) . On the other hand, the hM4Di is reportedly less effective at
inhibiting neuronal firing, so higher doses of CNO are occasionally used (Ray et al., 2011;
Sasaki et al., 2011). Beyond the inherent differences between Gq and Gi modulation of
neuronal excitability, the effects of the CNO-DREADD mediated manipulation depend on
the tissue distribution of the DREADD. For example, the hM3Dq mice originally
characterized express the Gq DREADD in all neurons of the cerebrum using the calmodulin
II kinase alpha promoter, creating a condition in which low doses of CNO could influence
neuronal activity on a large scale (Alexander et al., 2009). Conversely, the transgenic mice
used in Garner (2012) used the c-fos promoter to drive expression of the hM3Dq, so the
DREADD was expressed at lower levels and higher doses of CNO were necessary.
Furthermore, Krashes (2011) used a viral approach to express the hM3Dq in a small nucleus
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and administered 5.0 mg/kg CNO to elicit a response in these mice. From the body of work
performed with DREADDs to date, it can be seen that the dose of CNO is variable and
dependent on the type of DREADD and the expression system used.
To date, a majority of studies performed have used the intraperitoneal route of
administration, though other routes of administration are possible. Our lab has demonstrated
that CNO can be administered through the drinking water to create chronic administration
conditions (10 mg/kg/day, unpublished observations).
5. Untapped Utility of pharmacosynthetic Cell-type specific modulation
Pharmacosynthetics has untapped potential. The utilities not yet applied are inherent in the
nature of GPCR signaling in general and that of the pharmacosynthetic approach itself. With
the advent of more specific cell-type expression and measurement systems, DREADD
technology can be utilized to probe the mechanisms of pharmacotherapeutic efficacy and the
nature of GPCR-induced neuronal modulation. Here we will discuss currently underutilized
aspects of pharmacosynthetics.
5.1 Non-interfering modulation
An overlooked aspect of the pharmacosynthetic approach is the lack of interference with
endogenous signaling. Whereas the noninvasive aspect relates to the physiological benign
approaches to DREADD expression (transgenic mice), this lack of interference relates to the
nature of the experimental manipulation.
It has been posited elsewhere that ultimate function of the brain arises from the collection,
transmission, and integration of information (deCharms and Zador, 2000; Rolls and Treves,
2011). The brain encodes this information in the biochemicoelectric phenomena of neurons,
with the transmission and integration occurring through the function of action potentials,
neurotransmitters, and receptors. Various nuclei in the brain have been implicated in the
etiology of disease and the mechanism of action of therapeutics. Due to the limitations of
conventional approaches, it is difficult to separate the role of a nuclei's transmission,
integration, or generation of information in the etiology of the associated diseases. For
example, in a standard pharmacological approach, a small molecule ligand would be used to
modulate a particular receptor. In addition to inherent off-target confounds this approach,
receptor theory posits that any small molecule will compete with the endogenous ligand for
that receptor, ultimately functioning as an antagonist of the endogenous tone. This confound
applies to allosteric modulation as well. Whereas measurements from such a study would
implicate the role of receptor-mediated changes in the postsynaptic neuron, the phenomena
observed may be due, in part, to interference with the endogenous tone of ligand-receptor
signaling. Thus, the interpretation of such a study would not be able to resolve whether the
experimental manipulation modulated the integrator and transmitter of information (the
post-synaptic cell receiving input) or the information itself (the endogenous tone).
Pharmacosynthetics circumvents this confound by utilizing an exogenous receptor, leaving
the endogenous tone intact. This aspect of the DREADDs has been studied in vitro, where
the hM3Dq (with or without CNO) had minimal or no effect (dependent on measurement
system used) on the quaternary organization of wild-type and DREADD variants (hM3 and
hM3Dq) of the human muscarinic receptor (Alvarez-Curto et al., 2010). Furthermore, the
inert clozapine N-oxide does not interfere with endogenous receptor signaling. In this
manner, the experimenter can specifically modulate the neuronal nuclei in question,
independent of the information transfer. This non-interference of experimental manipulation
has yet to be explicitly utilized or considered in experimental design using the DREADDs.
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5.2 Cell-type specific GPCR signaling vs. “activation” and “silencing”
A majority of the studies to date have been designed and the data interpreted in the context
of DREADD-induced activation or silencing of neuronal activity. Whereas a result of Gαq-
coupled GPCR activation is depolarization and a result of Gαi-coupled GPCR activation is
hyperpolarization, these electrophysiological endpoints are only one result of GPCR
signaling pathways (Beaulieu and Gainetdinov, 2011; Deneris and Wyler, 2012). In the
pharmacosynthetic field, other physiological endpoints have heretofore been, for the most
part, overlooked. G-protein pathways are involved in a myriad of neuronal functions,
including gene regulation (West et al., 2002). Indeed, whereas the straightforward
interpretation and design of Gαq-mediated depolarization and Gαi-mediated
hyperpolarization is pragmatic for studies to date, the inherently metabotropic nature of
GPCR signaling needs to both be utilized and taken into account when considering
pharmacosynthetics for experimental manipulation.
An application of pharmacosynthetics that would utilize this facet of DREADDs is
determining the particular G-protein signaling necessary for therapeutic efficacy. The advent
of functional selectivity has caused a sea change in our understanding of GPCR function, in
that the simple distinction of ligands as agonists, antagonists, and inverse agonists no longer
exists (Allen and Roth, 2011; Urban et al., 2007). Instead, it is now appreciated that a
particular small molecule can impart intracellular signaling entirely dependent on the
signaling machinery present in a given cell type. Thus, a given “agonist” to a receptor in cell
population A can induce receptor-mediated signaling, whereas the same “agonist” at the
same receptor in cell population B can have no effect or a different effect entirely.
Furthermore, the observed phenomena to date suggest that the signaling induced upon ligand
binding is dependent on the small molecule - a particular “agonist” X to a receptor can
induce a particular GPCR-mediated signaling phenomenon (such as cAMP accumulation),
whereas another “agonist” Y at the same receptor can cause entirely different GPCR-
mediated signaling phenomenon (such as beta-arrestin signaling). This “functional
selectivity” of small molecule ligands opens a new chapter in small molecule drug discovery
for G-protein coupled receptors, an already well-validated drug targeted.
This new effort is hindered by an unfortunate fusion of the phenomena to be exploited and
the nature of modern drug discovery efforts. To date, a majority of drug discovery efforts
use cultured cell populations as a model system to study GPCR signal transduction. In what
is termed “reverse pharmacology”, a receptor is isolated from the organism and its signal
transduction properties are studied in the cultured cell populations (Figure 2, top). Due to the
implications of functional selectivity, these cultured cell populations, in combination with
the type of GPCR being studied and the chemical space of the drug, synergize to produce the
signaling phenomena observed. Thus, the observed phenomena are dependent upon the
model cell system used. Any subsequent translation of a drug's function to the whole
organism is due to fortuitous similarity of cellular phenotype between the model system and
the whole organism. While reverse pharmacology has created a wealth of information
regarding the relationship between the structure of a small molecule ligand and the response
of the receptor, the translation of these findings to the whole organism, in terms of
therapeutic efficacy, has been less fruitful. A well-known contributor to inverse
pharmacology's lack of success is that these chemicals can have off-target effects when
reintroduced to the whole organism. While this confound is measurable and perhaps
rectified with further compound development, a second unmeasurable confound is the
differential receptor function in the native cellular environment compared to the cultured
cell. Whereas a chemical may induce a unique signaling state when it is bound to a receptor
in the model cell culture system, the native neuronal environment of the receptor may not
have cellular factors capable of recognizing the signal being transduced by the chemical-
receptor complex (for review see Allen and Roth 2011).
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Pharmacosynthesis creates a means to overcome this confound. The opposite approach to
reverse pharmacology can be termed “directed” pharmacology, in which the signaling of a
particular receptor is designed and characterized in the cultured cell system and then
introduced into the whole organism (Figure 2, bottom). An aspect of the DREADDs not
fully appreciated is the fact that mutations used to engender CNO modulation and rectify
endogenous neurotransmitter modulation are functionally benign. That is, the receptor
behaves for all intents and purposes identical to the wild-type receptor (Alvarez-Curto et al.,
2011). This facet of the DREADDs permits manipulation of intracellular receptor
components that can affect the coupling of the receptor to downstream effectors. Guettier et.
al. (2009) recognized this and swapped the intracellular loops of the hM3Dq with the loops
of the turkey β1-adrenergic receptor to confer Gs-coupling of the DREADD. Although the
exact mechanism of ligand induced GPCR activation is unknown, is has been hypothesized
to be a shared mechanism across GPCRs. For instance, many groups have reported creating
chimeras of the transmembrane and extracellular portions of GPCR type A with the
intracellular portions of GPCR type B to confer type B receptor signaling following
application of ligands for receptor type A (Kim et al., 2005; Marion et al., 2006; Oh et al.,
2010). If this holds true across receptor types, one can hypothesize that the intracellular
components of a DREADD can be replaced with those of a different receptor to confer CNO
modulation of that receptor's signaling. DREADDs could be designed to modulate unique
and specific signal transduction pathways in cell culture systems, and then these DREADD
variants could be inserted in vivo to determine whether the designed functional selectivity
translates into usefully different neuronal signaling and function (Figure 2E-G). Because the
specificity of CNO for the DREADD is pharmacologically unprecedented, this approach
would allow us to introduce designer signaling into specific cell types and study the
subsequent physiological response to this signaling. Indeed, recent efforts have culminated
in the creation of optically activated β-arrestin functionally-selective DREADDs (Lee and
Roth, in preparation) which allow for the precise spatio-temporal control of arrestin
signaling.
In one sense, this potential application can invert our standard means of molecular
pharmacology. Instead of isolating the signal transduction device (the GPCR) and studying
its effects on non-native signal transduction cascades (Figure 2A,B), we can now study the
ligand-receptor complex as a single entity. The results of these studies will be correlative
information between the signaling transduction induced by CNO/DREADDs in model cell
systems and the physiological response of the CNO/DREADDs in the whole organism
(Figure 2E,F). These data could then be used to design small-molecule ligands (or
collections of small molecule ligands) that mimic the CNO/DREADD signaling phenomena
observed in the cultured cell system (Figure 2I). This approach would essentially invert the
process of drug discovery: instead of designing a chemical to elicit an efficacious
physiological response, we could directly design an efficacious signaling state and then
create a chemical (or chemicals) that can recapitulate the designed state. To our knowledge,
only the DREADD technology provides this utility, capitalizing on the drug-like modulation
of selective but dispersed neuronal populations.
6 Future Developments Necessary for Increased Utility
6.1 A non CNO-based DREADD
First and foremost, the development of a second, non CNO-based DREADD would be the
most advantageous development to further our neuropharmacological understanding of the
brain. The availability of an additional DREADD could permit the mapping of functional
neuronal circuits, for example, by placing an excitatory non CNO-based DREADD upstream
of a nuclei modulated by the hM4Di. In this fashion, one could determine the functional
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involvement of a series of nuclei posited to be integral for a given neuronal circuit. Indeed,
we have recently created a new Gi-biased DREADD to this end (Vardy et al, in preparation).
6.2 Enhanced genetic expression strategies
The cell-type specificity afforded by the pharmacosynthetic approach is dependent upon the
available genetic targeting approaches. As mentioned above, the virally mediated gene
transfer provides for the most effective targeting of small nuclei, whereas the genomic
modification approach is the most truly non-invasive means to obtain cell-type specific
DREADD expression, though the expression patterns obtained can be off-target (due to the
nature of the gene promoter used). Furthermore, existing technologies have been designed to
be versatile as opposed to specific, creating scenarios in which multiple transgenes must be
present in a mouse to confer DREADD expression or generations of germline recombination
must be undertaken to obtain a useable mouse. Ideally, a DREADD could be expressed in
the intended neuronal population using as few transgenes as possible. This both simplifies
mouse breeding requirements and would “future proof” a given mouse line. I.e., if a single
transgene mouse was created that expressed a DREADD in a specific population, a second
transgenic mouse carrying a non CNO-based DREADD could be crossed with this mouse.
Thus, one could have two different DREADDs expressed using only two transgenes.
6.3 Complete experimental control of signal transduction
The supposition that signal transduction can be separated from the physiological response, in
addition to the implications of functional selectivity, necessitate a further rightward shift in
our control and understanding of the pharmacological equation. Whereas the
pharmacosynthetic state of the art currently provides for control of the ligand-receptor pair,
the physiological response is still dependent on the effectors present in a given cell type. In
the future, it may be possible to control the ligand-receptor-effector triplet (or the ligand-
receptor-effector-effector quartet, etc), providing unprecedented depth of pharmacological
manipulation as was recently described by Yagi et al, (2011). For instance, one can imagine
creating polycistronic transgenes that contain custom effectors designed to solely interact
with designer receptors (Fig 3c). In this manner, one could truly synthesize signaling states
in specific cell populations to create an end-goal for pharmacotherapeutic development.
These custom signaling cascades will provide an unprecedented level of signaling control
and definitively determine the type of signaling required for a particular physiological
response.
7 Conclusions
7.1 Key Difference Between Optogenetics and Pharmacosynthetics
It is important to note the differences between the pharmacosynthetic approach and the
optogenetic approach. Using optogenetics, one can gain precise spatio-temporal control of
neuronal firing using a combination of light and transgenic expression of engineered
receptors. Among the optogenetic tools available, one difference is the level of invasiveness
required for experimental manipulation when compared to pharmacosynthetics. Using
optogenetics, one must deliver light to neurons- a process that currently requires
implantation of fiber optics into the brain. Notwithstanding the proper implementation of
control conditions, experiments can be imagined for which survival surgeries (and the
subsequent hardware attachment) present insurmountable confounds. In its most
noninvasive form - genomic transgene – pharmacosynthetic manipulation can be achieved
with minimal invasiveness to the organism using peripheral administration of CNO (or even
via food or drinking water). However, the prevalent use of virally mediated gene transfer in
pharmacosynthetics (Table 1) would indicate that the level of initial invasiveness between
approaches is similar. A second difference is the type of neuronal modulation afforded.
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Currently, the most widespread variation of optogenetics utilizes the channelrhodopsins, a
family of light activated ion channels that directly modulate the ion conductance of neuronal
membranes and either hyperpolarize or depolarize neurons. In contrast, DREADDs
modulate G-protein mediated signaling – signaling cascades for which neuronal
hyperpolarization or depolarization are only one outcome. However, there are optogenetic
tools available – the OptoXRs - that modulate G-protein mediated signaling using light,
though these have not gained widespread use.
Whereas the type of signaling afforded by these two approaches is not considerably
different, nor the level of invasiveness considering the use of viral-mediated gene transfer, it
can be argued that the nature of the neuronal modulation provided by these two technologies
is what clearly separates them as distinct experimental tools with considerably different
utility. The nature of the neuronal modulation created using pharmacosynthetics more
closely resembles the hormonal signaling mechanisms found in the brain, in that the
modulatory agent (CNO) “lingers” in the extraneuronal space and activates signal
transduction mechanisms (GPCRs) dependent on diffusion, clearance, and receptor
regulatory mechanisms (internalization, desensitization). This nature of activity more closely
resembles the nature of metabotropic neurotransmitter or drug activity than any other
process. On the other hand, optogenetics more closely resembles the electrochemical
functionality of neurons. That is, the manipulation of membrane conductance more closely
resembles the end result of factor-induced neuronal changes. In other words,
pharmacosynthetics permits for the study of neuronal modulation itself, whereas
optogenetics permits for the study of what a modulated neuron actually does in the brain.
While these differences should fundamentally affect the type of experimentation performed
with the respective technologies, pharmacosynthetics has yet to be fully implemented in this
fashion.
7.2 Concluding remarks
Pharmacosynthetics provides an effective means to study the physiological effects of
artificial, drug-like modulation of distinct neuronal populations. The specificity and
exclusivity of GPCR modulation afforded by the technology can be utilized to explore
mechanisms of therapeutic efficacy to further the development of small-molecule
therapeutics. Further development of pharmacosynthetics will create levels of experimental
manipulation that will challenge our conventional understanding of signal transduction and
pharmacology. With this reimagination of this technology, it can be seen that the
pharmacosynthetic approach provides unprecedented ability to truly answer the defining
question of neuropharmacology – how do drugs modulate brain activity?
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Figure 1. Properties and Composition of Currently Utilized DREADDs
(A) Gray box indicates two-way selectivity component of DREADDs. Solid lines with
arrows indicate that the source compound activates the receptor at the arrow's target. Dashed
lines with circles indicate that the source compound does not activate the targeted receptor.
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Figure 2. An application of pharmacosynthetics in drug discovery
(A-D) Conventional drug discovery efforts – reverse pharmacology. In this approach, a drug
target is selected (usually based on previous success at that particular target) and isolated
from the organism. A particular type of signaling is hypothesized to be efficacious, and
chemicals are created that cause the receptor to produce that signaling state in cultured cells.
The drug is then reintroduced to the model organism and tested for therapeutic efficacy. (E-
I) A theoretical workflow of drug discovery efforts using pharmacosynthetics, here termed
direct pharmacology. In this approach, functionally selective DREADDs ( f(x)DREADD,
where x=signaling type) are created by modifying DREADDs to modulate distinct signaling
phenomena in cultured cells while maintaining their DREADD properties. These
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f(x)DREADDs are then expressed in therapeutically relevant neuronal populations. These
mice are then tested in animal models of therapeutic efficacy. If a particular f(x)DREADD
in a particular neuronal population is efficacious, then that cell population is profiled to find
druggable targets. These druggable targets are then isolated (expressed in cultured cells) and
chemicals are created that modulate these targets to reproduce the signaling state created by
the f(x)DREADD. Chemicals that successfully recapitulate the f(x)DREADD-induced
signaling are then tested in animal models of efficacy.
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Figure 3. Shifting the pharmacological equation
(A) The conventional understanding of pharmacology posits that drugs interact with
physiological systems to produce a physiological response. This interaction takes place
through the transduction of a signal (either an endogenous chemical or an exogenous drug)
via signal transduction mechanisms. The current depth of pharmacology defines the signal
as the ligand itself, freeing the signal transducer and the signal transduction cascade to blend
with the physiological response. (B) Pharmacosynthetic depth of pharmacology. Using
pharmacosynthetics, both the ligand and the signal transducer (receptor) shift to the left side
of the equation, creating a more defined signal with less signal transduction noise. (C)
Future Pharmacosynthetics. With further development, a deeper level of pharmacosynthetic
Farrell and Roth Page 21













manipulation can be obtained. With the entirety of the signal transduction cascade under
experimental control, we could potentially understand the type of signal needed to evoke a
particular physiological response.
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